Lipid-altering therapy and Atrial fibrillation

Justin M. Bachmann, Maulik Majmudar, Christine Tompkins, Roger S Blumenthal, Joseph Marine

Research output: Contribution to journalArticle

Abstract

Atrial fibrillation (AF) is a common cardiac arrhythmia with significant morbidity and public health cost. Because of limitations of efficacy and safety of conventional antiarrhythmic agents, alternative therapies for AF are needed. The potential antiarrhythmic properties of lipid-altering therapy, including the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and fish oils, are increasingly recognized, particularly in light of their potential anti-inflammatory properties. This review examines the known effects of lipid-altering therapy on atrial arrhythmias in both experimental and clinical settings. Inflammatory states, such as postcardiac surgery and AF of recent onset, show promise as targets. In contrast, lipid-lowering therapy is less likely to affect longstanding persistent AF. Current recommendations for the use of lipid-altering therapy for prevention and treatment of AF are summarized.

Original languageEnglish (US)
Pages (from-to)197-204
Number of pages8
JournalCardiology in Review
Volume16
Issue number4
DOIs
StatePublished - Jul 2008

Fingerprint

Atrial Fibrillation
Lipids
Cardiac Arrhythmias
Therapeutics
Fish Oils
Complementary Therapies
Health Care Costs
Oxidoreductases
Anti-Inflammatory Agents
Public Health
Morbidity
Safety

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Lipid-altering therapy and Atrial fibrillation. / Bachmann, Justin M.; Majmudar, Maulik; Tompkins, Christine; Blumenthal, Roger S; Marine, Joseph.

In: Cardiology in Review, Vol. 16, No. 4, 07.2008, p. 197-204.

Research output: Contribution to journalArticle

Bachmann, Justin M. ; Majmudar, Maulik ; Tompkins, Christine ; Blumenthal, Roger S ; Marine, Joseph. / Lipid-altering therapy and Atrial fibrillation. In: Cardiology in Review. 2008 ; Vol. 16, No. 4. pp. 197-204.
@article{b0afaa1579654f6bbb10e8e3681d4218,
title = "Lipid-altering therapy and Atrial fibrillation",
abstract = "Atrial fibrillation (AF) is a common cardiac arrhythmia with significant morbidity and public health cost. Because of limitations of efficacy and safety of conventional antiarrhythmic agents, alternative therapies for AF are needed. The potential antiarrhythmic properties of lipid-altering therapy, including the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and fish oils, are increasingly recognized, particularly in light of their potential anti-inflammatory properties. This review examines the known effects of lipid-altering therapy on atrial arrhythmias in both experimental and clinical settings. Inflammatory states, such as postcardiac surgery and AF of recent onset, show promise as targets. In contrast, lipid-lowering therapy is less likely to affect longstanding persistent AF. Current recommendations for the use of lipid-altering therapy for prevention and treatment of AF are summarized.",
author = "Bachmann, {Justin M.} and Maulik Majmudar and Christine Tompkins and Blumenthal, {Roger S} and Joseph Marine",
year = "2008",
month = "7",
doi = "10.1097/CRD.0b013e318177271d",
language = "English (US)",
volume = "16",
pages = "197--204",
journal = "Cardiology in Review",
issn = "1061-5377",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Lipid-altering therapy and Atrial fibrillation

AU - Bachmann, Justin M.

AU - Majmudar, Maulik

AU - Tompkins, Christine

AU - Blumenthal, Roger S

AU - Marine, Joseph

PY - 2008/7

Y1 - 2008/7

N2 - Atrial fibrillation (AF) is a common cardiac arrhythmia with significant morbidity and public health cost. Because of limitations of efficacy and safety of conventional antiarrhythmic agents, alternative therapies for AF are needed. The potential antiarrhythmic properties of lipid-altering therapy, including the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and fish oils, are increasingly recognized, particularly in light of their potential anti-inflammatory properties. This review examines the known effects of lipid-altering therapy on atrial arrhythmias in both experimental and clinical settings. Inflammatory states, such as postcardiac surgery and AF of recent onset, show promise as targets. In contrast, lipid-lowering therapy is less likely to affect longstanding persistent AF. Current recommendations for the use of lipid-altering therapy for prevention and treatment of AF are summarized.

AB - Atrial fibrillation (AF) is a common cardiac arrhythmia with significant morbidity and public health cost. Because of limitations of efficacy and safety of conventional antiarrhythmic agents, alternative therapies for AF are needed. The potential antiarrhythmic properties of lipid-altering therapy, including the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and fish oils, are increasingly recognized, particularly in light of their potential anti-inflammatory properties. This review examines the known effects of lipid-altering therapy on atrial arrhythmias in both experimental and clinical settings. Inflammatory states, such as postcardiac surgery and AF of recent onset, show promise as targets. In contrast, lipid-lowering therapy is less likely to affect longstanding persistent AF. Current recommendations for the use of lipid-altering therapy for prevention and treatment of AF are summarized.

UR - http://www.scopus.com/inward/record.url?scp=49149085882&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49149085882&partnerID=8YFLogxK

U2 - 10.1097/CRD.0b013e318177271d

DO - 10.1097/CRD.0b013e318177271d

M3 - Article

VL - 16

SP - 197

EP - 204

JO - Cardiology in Review

JF - Cardiology in Review

SN - 1061-5377

IS - 4

ER -